Literature DB >> 30544145

Current Activities of the Coalition of Cancer Cooperative Groups.

Monica M Bertagnolli1, Susan M Blaney2, Charles D Blanke3, Walter J Curran4, Janet Dancey5, Robert S Mannel6, Peter J O'Dwyer7, Mitchell D Schnall8, Norman Wolmark9.   

Abstract

The Coalition of Cancer Cooperative Groups is an organization representing the interests of patients and researchers who conduct research through the National Cancer Institute-supported National Clinical Trials Network (NCTN). The NCTN provides a crucial mechanism for executing practice-changing cancer clinical research to achieve both cancer control and development of new therapeutic agents or modality approaches. Public funding, largely through the National Cancer Institute, ensures that the work of the NCTN achieves important research that would not otherwise be accomplished in the private sector. In fall 2017, the Coalition of Cancer Cooperative Groups convened a Scientific Leadership Council to review the current state of the network with regard to research capabilities and to develop a list of research questions to be prioritized by the network. This report presents the results of this meeting, detailing a roadmap for future work by the NCTN.

Entities:  

Mesh:

Year:  2019        PMID: 30544145      PMCID: PMC6657272          DOI: 10.1093/jnci/djy190

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  26 in total

1.  The coalition of cancer cooperative groups.

Authors:  Robert L Comis
Journal:  J Oncol Pract       Date:  2007-09       Impact factor: 3.840

2.  A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program.

Authors:  John F Scoggins; Scott D Ramsey
Journal:  J Natl Cancer Inst       Date:  2010-08-03       Impact factor: 13.506

3.  Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.

Authors:  David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Joseph P Costantino; Takamaru Ashikaga; Donald L Weaver; Eleftherios P Mamounas; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh Mc Scarth; Norman Wolmark
Journal:  Lancet Oncol       Date:  2010-10       Impact factor: 41.316

4.  Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509.

Authors:  Elizabeth M Blanchard; James Moon; Paul J Hesketh; Karen Kelly; Antoinette J Wozniak; John Crowley; David Gandara
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

Review 5.  Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.

Authors:  Richard A Larson; Richard M Stone; Robert J Mayer; Charles A Schiffer
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

Review 6.  Patient-reported outcomes and the evolution of adverse event reporting in oncology.

Authors:  Andy Trotti; A Dimitrios Colevas; Ann Setser; Ethan Basch
Journal:  J Clin Oncol       Date:  2007-11-10       Impact factor: 44.544

Review 7.  Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.

Authors:  Mark R Green; Stephen L George; Richard L Schilsky
Journal:  Semin Oncol       Date:  2008-10       Impact factor: 4.929

Review 8.  The Southwest Oncology Group: progress in cancer research.

Authors:  Charles A Coltman
Journal:  Semin Oncol       Date:  2008-10       Impact factor: 4.929

9.  Adjuvant chemotherapy in older women with early-stage breast cancer.

Authors:  Hyman B Muss; Donald A Berry; Constance T Cirrincione; Maria Theodoulou; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn G Dressler; Harvey J Cohen; Heather P Becker; Patricia A Kartcheske; Judith D Wheeler; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Gustav Magrinat; Gutav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Larry Norton; Clifford A Hudis; Eric P Winer
Journal:  N Engl J Med       Date:  2009-05-14       Impact factor: 91.245

Review 10.  Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors.

Authors:  John M Kirkwood; Ahmad Tarhini; Joseph A Sparano; Prapti Patel; Joan H Schiller; Maxwell T Vergo; Al B Benson Iii; Hussein Tawbi
Journal:  Cancer Treat Rev       Date:  2012-04-19       Impact factor: 12.111

View more
  1 in total

1.  Creating and Implementing a Principal Investigator Tool Kit for Enhancing Accrual to Late Phase Clinical Trials: Development and Usability Study.

Authors:  Alexandra Thomas; Kristin A Higgins; Nancy Soto; Rebecca Paulus; Thomas J George; Thomas B Julian; Sharon Hartson Stine; Merry Jennifer Markham; Maria Werner-Wasik
Journal:  JMIR Cancer       Date:  2022-08-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.